company background image
CYCC

Cyclacel Pharmaceuticals NasdaqCM:CYCC Stock Report

Last Price

US$0.77

Market Cap

US$9.6m

7D

-13.5%

1Y

-77.9%

Updated

01 Dec, 2022

Data

Company Financials +
CYCC fundamental analysis
Snowflake Score
Valuation3/6
Future Growth0/6
Past Performance0/6
Financial Health5/6
Dividends0/6

CYCC Stock Overview

Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases.

Cyclacel Pharmaceuticals, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Cyclacel Pharmaceuticals
Historical stock prices
Current Share PriceUS$0.77
52 Week HighUS$4.53
52 Week LowUS$0.76
Beta1.13
1 Month Change-38.93%
3 Month Change-54.47%
1 Year Change-77.89%
3 Year Change-92.73%
5 Year Change-97.90%
Change since IPO-99.99%

Recent News & Updates

Cyclacel Pharmaceuticals (NASDAQ:CYCC) Will Have To Spend Its Cash Wisely

Aug 17
Cyclacel Pharmaceuticals (NASDAQ:CYCC) Will Have To Spend Its Cash Wisely

Cyclacel: Trading At Less Than Half Its Cash Value, Near-Term Catalysts, No Obvious Bear Thesis

Aug 07

Recent updates

Cyclacel Pharmaceuticals (NASDAQ:CYCC) Will Have To Spend Its Cash Wisely

Aug 17
Cyclacel Pharmaceuticals (NASDAQ:CYCC) Will Have To Spend Its Cash Wisely

Is Cyclacel Pharmaceuticals (NASDAQ:CYCC) In A Good Position To Invest In Growth?

Apr 15
Is Cyclacel Pharmaceuticals (NASDAQ:CYCC) In A Good Position To Invest In Growth?

Shareholder Returns

CYCCUS BiotechsUS Market
7D-13.5%2.7%1.4%
1Y-77.9%-10.3%-16.1%

Return vs Industry: CYCC underperformed the US Biotechs industry which returned -10.2% over the past year.

Return vs Market: CYCC underperformed the US Market which returned -14.8% over the past year.

Price Volatility

Is CYCC's price volatile compared to industry and market?
CYCC volatility
CYCC Average Weekly Movement10.6%
Biotechs Industry Average Movement11.2%
Market Average Movement7.4%
10% most volatile stocks in US Market15.6%
10% least volatile stocks in US Market3.3%

Stable Share Price: CYCC is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 11% a week.

Volatility Over Time: CYCC's weekly volatility (11%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
n/an/aSpiro Rombotishttps://www.cyclacel.com

Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company’s development programs include fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and CYC140, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced leukemias and solid tumors. Its development programs also comprise Sapacitabine, a novel nucleoside analog that is orally available prodrug of CNDAC, which is in Phase 1/2 clinical trials to treat acute myeloid leukemia and myelodysplastic syndrome; and seliciclib, a CDK inhibitor that is in Phase 2 investigator-sponsored trials (IST) for Cushing’s disease, as well as in Phase 1/2 IST for the treatment for advanced rheumatoid arthritis.

Cyclacel Pharmaceuticals, Inc. Fundamentals Summary

How do Cyclacel Pharmaceuticals's earnings and revenue compare to its market cap?
CYCC fundamental statistics
Market CapUS$9.65m
Earnings (TTM)-US$19.27m
Revenue (TTM)n/a

0.0x

P/S Ratio

-0.5x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
CYCC income statement (TTM)
RevenueUS$0
Cost of RevenueUS$3.03m
Gross Profit-US$3.03m
Other ExpensesUS$16.25m
Earnings-US$19.27m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-1.54
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did CYCC perform over the long term?

See historical performance and comparison